Physician profile
David Miller
NPI 1417487695
$9,598.67
in general payments reported to CMS, 2019-2025
22 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what 79% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.99 · 2023: $2,171 · 2024: $5,502 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,537 · Travel and Lodging: $3,592 · Consulting Fee: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,536.68 |
| Travel and Lodging | $3,592.00 |
| Consulting Fee | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,833.30 | 2022-2025 | Tactra, General - Erectile Dysfunction, Ams 700 |
| Coloplast Corp | $3,359.18 | 2023-2025 | Titan |
| Endo USA, INC. | $413.60 | 2024-2025 | Xiaflex |
| Sumitomo Pharma America, INC. | $345.75 | 2024-2025 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $313.83 | 2024-2025 | Aquabeam System |
| Endo Pharmaceuticals INC. | $247.59 | 2023-2024 | Xiaflex |
| Urogen Pharma, INC. | $211.88 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $140.35 | 2024-2025 | Provenge |
| Abbvie INC. | $140.00 | 2024-2025 | |
| Heron Therapeutics, INC. | $121.92 | 2023 | Aponvie |
| Calyxo, INC. | $85.63 | 2025 | Cvac Aspiration System |
| Janssen Biotech, INC. | $82.34 | 2025 | Erleada |
| Antares Pharma, INC. | $59.40 | 2024-2025 | Xyosted |
| Teleflex LLC | $51.60 | 2024-2025 | Urolift |
| Bayer Healthcare Pharmaceuticals INC. | $38.84 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunitybio, INC. | $30.78 | 2024 | |
| Merck Sharp & Dohme LLC | $26.42 | 2025 | Keytruda, Welireg |
| Laborie Medical Technologies Corp. | $24.70 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $20.79 | 2024 | Imfinzi |
| Pfizer INC. | $19.67 | 2025 | |
| Myriad Genetic Laboratories, INC. | $17.05 | 2025 | Prolaris |
| 180 Medical, INC. | $14.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.